--Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive topline results from its Phase 3 ...

BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

ARIKAYCE is administered once daily using the Lamira ® Nebulizer System manufactured by PARI Pharma GmbH (PARI). ARIKAYCE is not approved in any country other than the United States. About PARI Pharma ...

—Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker— —Data to ...

Hemoptysis has been reported with the use of ARIKAYCE in the clinical trials. Hemoptysis was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (17.9%) compared ...

ARIKAYCE is delivered by a novel inhalation device, the Lamira ® Nebulizer System, developed by PARI. Lamira ® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a ...

Arikayce (amikacin liposome) is a brand-name inhalation suspension that’s prescribed to treat a certain bacterial lung infection. As with other drugs, Arikayce can cause side effects, such as cough, ...

ARIKAYCE is delivered by a novel inhalation device, the Lamira® Nebulizer System, developed by PARI. Lamira® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a ...

—QOL-B Respiratory Domain Shown to Work Effectively as Patient-Reported Outcome Tool in Patients with MAC Lung Disease; to be Proposed to FDA as Primary Endpoint in ENCORE with No Modifications— ...

—Additionally, Insmed Provides Independent Research Grant to the American Thoracic Society for a Landmark Quality Initiative to Improve Diagnosis of Bronchiectasis across the U.S.— BRIDGEWATER, N.J., ...